Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Update

18 Jan 2012 07:00

RNS Number : 7281V
Plant Health Care PLC
18 January 2012
 



 

 

18 January 2012

 

PLANT HEALTH CARE PLC

("Plant Health Care" or "the Company")

 

Trading Update

 

Plant Health Care (AIM: PHC.L), a leading provider of naturally-derived products to the agriculture industry, provides the following post year-end update ahead of the announcement of its full year results to 31 December 2011, which are expected on 27 February 2012. All results provided are preliminary and subject to completion of the 2011 audit.

 

The Board is pleased to report that the operating loss before share-based payments is expected to be approximately $6.7 million, on revenues of $7.9 million. Due to tight control over operating costs, the operating loss was better than expectations, with revenues being slightly less than expectations. As a consequence of the lower losses and strong collections from debtors, the Company is expecting to report cash and cash equivalents at year-end of US$14 million, significantly ahead of expectations. The Company is focused on accelerating the development and improving performance of its core Harpin and Myconate technologies. As a result, R&D spend on next generation product development and formulations doubled in 2011, and is expected to increase at a similar rate in 2012 to over $1mm.

 

The Company has also been strongly focused on the pursuit of further significant partnering relationships. The following is a progress report on the most significant aspects of the business:

 

·; On-ground sales (end-user application of the product) of Harpin in the US rose approximately 40% in 2011 from programmes driven by the Company and its partners to increase market awareness and acceptance of Harpin as a critical biological enhancement to existing seed treatment options. As a result of in-hand distributor orders, we expect 2012 on-ground sales to more than triple 2011 levels. On-ground sales of Harpin have also grown rapidly in Mexico and South Africa as a result of initiatives in those markets. Both countries experienced roughly 50% growth in on-ground sales in 2011, and we expect this to accelerate by 70% in 2012.

·; As a result of the success of on-ground sales, Plant Health Care is in discussions with a number of global and regional agrichemical and agricultural supply companies to further exploit its Harpin and Myconate technologies, on new crops, by new product applications and in new geographical regions. Good progress is being made towards finalising substantial new partnering agreements during 2012.

·; 2011 delivered the best set of trial results with Harpin and Myconate that the Company has ever experienced. The strength of these results has helped escalate our partnering discussions.

·; We have developed six next generation Harpin product candidates that will be moving into initial field trials in 2012. All six candidates have exhibited significantly stronger attributes in greenhouse trials than the Harpin products that are currently in the market.

 

The Board has been greatly encouraged by the progress made in the past 12 months and believes that the increasing use of Harpin and Myconate-based products and the pipeline of potential new partnering transactions will ensure that our present cash resources will be sufficient to fund the Company through to profitability in future periods.

 

 

John Brady, Chief Executive of Plant Health Care, said: "The sale of the US retail and landscape business at the start of 2011 has allowed us to focus on obtaining licensing agreements for Harpin and Myconate and on supporting our partners in the introduction of new products. Good progress across the business and our strong trial results mean we remain confident of substantial progress and further important developments during 2012."

 

-Ends-

For further information please contact:

 

Plant Health Care plc 

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

 

Evolution Securities

Tavistock Communications

Jeremy Ellis

Jeremy Carey/Simon Compton

Tel: +44-20-7071-4300

Tel: +44-20-7920-3150

 

jeremy.ellis@evosecurities.com

 

jcarey@tavistock.co.uk

scompton@tavistock.co.uk

 

Notes to editors:

About Plant Health Care plc: Plant Health Care plc ("PHC") is a leading provider of naturally derived products for plants and soil. Established in 1995 in Pittsburgh (Pennsylvania) in the United States, PHC currently has approximately 40 employees and has operations in the United States, Mexico, the United Kingdom, Spain, and the Netherlands.

 

The Company's ordinary shares have been quoted on the AIM Market of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/ mnemonic: PHC).

 

Trademarks:

Myconate and Harpin are trademarks or trade names which Plant Health Care owns or which others own and license to Plant Health Care for use.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBUBRUVAAAAR
Date   Source Headline
20th Apr 20227:00 amRNSHolding(s) in Company
19th Apr 20221:46 pmRNSNotice of results and investor presentation
11th Apr 202212:52 pmRNSHolding(s) in Company
1st Apr 20227:00 amRNSNew Distribution agreement with Ager Agro
14th Mar 202212:49 pmRNSHolding(s) in Company
11th Mar 202212:19 pmRNSHolding(s) in Company
3rd Feb 202212:56 pmRNSHolding(s) in Company
1st Feb 20221:16 pmEQSPlant Health Care, plc
1st Feb 20227:00 amRNS2021 Trading Statement
31st Jan 20227:00 amRNSPHC949 product registration submitted to the EPA
17th Jan 20227:00 amRNSInvestor Presentation
15th Dec 20217:00 amRNSWilbur Ellis and Plant Health Care discussion
13th Dec 20217:00 amRNSCommercial scale manufacturer for Saori
30th Nov 20214:36 pmRNSPrice Monitoring Extension
20th Oct 20216:03 pmRNSExercise of Options
22nd Sep 20217:00 amRNSNew agreement with Nutrien for Saori launch
22nd Sep 20217:00 amRNSInterim Report 30 June 2021
21st Sep 20214:41 pmRNSSecond Price Monitoring Extn
21st Sep 20214:35 pmRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSArgentina approves Harpin as a seed treatment
24th Aug 20217:00 amRNSInvestor Presentation
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.